FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an WELC		2. Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [EIGR]								(Check all a Dire		olicable) ctor	g Person(s) to Issuer 10% Owner Other (specify						
(Last) 350 CAM	Last) (First) (Middle) 350 CAMBRIDGE AVE, SUITE 350							3. Date of Earliest Transaction (Month/Day/Year) 06/20/2016								er (give title w) Chief Finai	below) ncial Officer		
(Street) PALO ALTO CA 94306 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv _ine) X	,				
		Tabl	e I - I	Non-Deriv	vative	Sec	uritie	es Ac	cquire	ed, D	isposed o	f, or E	Benefici	ially	Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					.	Execution Date,		·			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Secu Bene		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									v	Amount	(A) or (D)	Price	Trans		action(s) 3 and 4)		(111341.4)		
Common	Stock	016	6			P		2,000	A	\$19.79)62 ⁽¹⁾		2,000	D					
Common Stock 06/22/201						16			P		500	A	\$19.7	944	2,500		D		
		Та	ble I								oosed of, convertib				vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		te Exer ation D th/Day/		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			vative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

Remarks:

/s/ James H. Welch

06/22/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.695 to \$19.8752, inclusive. The reporting person undertakes to provide to Eiger BioPharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.